Rani Therapeutics Holdings (RANI) Total Current Liabilities (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Total Current Liabilities of $13.9 million for Q1 2026, down 31.17% year-over-year from $20.1 million in Q1 2025, and up 9.36% quarter-over-quarter from $12.7 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Total Current Liabilities (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $13.9 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 31.17% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $13.9 million (down 31.17% YoY), while the FY2025 annual figure was $12.7 million, down 36.31% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $13.9 million, up from $12.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $20.6 million in Q2 2025, with the low at $4.2 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $12.7 million (2025), against an average of $12.0 million.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities plunged 42.82% in 2022, then soared 189.12% in 2024.
- Rani Therapeutics Holdings' Total Current Liabilities stood at $4.8 million in 2022, then soared by 65.92% to $8.0 million in 2023, then jumped by 148.98% to $19.9 million in 2024, then slumped by 36.31% to $12.7 million in 2025, then rose by 9.36% to $13.9 million in 2026.
- Business Quant data shows RANI's Total Current Liabilities at $13.9 million in Q1 2026, $12.7 million in Q4 2025, and $19.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | 10.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.64 Mn |
| Mar 31, 2026 | 13.86 Mn |
| Dec 31, 2025 | 12.67 Mn |
| Sep 30, 2025 | 19.14 Mn |
| Jun 30, 2025 | 20.62 Mn |
| Mar 31, 2025 | 20.13 Mn |
| Dec 31, 2024 | 19.89 Mn |
| Sep 30, 2024 | 20.21 Mn |
| Jun 30, 2024 | 16.58 Mn |
| Mar 31, 2024 | 13.38 Mn |
| Dec 31, 2023 | 7.99 Mn |
| Sep 30, 2023 | 7.35 Mn |
| Jun 30, 2023 | 5.74 Mn |
| Mar 31, 2023 | 5.15 Mn |
| Dec 31, 2022 | 4.82 Mn |
| Sep 30, 2022 | 7.19 Mn |
| Jun 30, 2022 | 5.35 Mn |
| Mar 31, 2022 | 4.16 Mn |
| Dec 31, 2021 | 2.64 Mn |
| Sep 30, 2021 | 5.25 Mn |